Eltrombopag added to prednisolone for newly diagnosed immune thrombocytopenia
Tests eltrombopag as first treatment in adults newly diagnosed with immune thrombocytopenia.
Key facts
- Who runs it
- Renata PLC
- Where
- Bangladesh1 site in 1 countryChoose a country to see its sites
- Trial code
- Registry title
- Role of Eltrombopag as First Line Therapy in Primary Immune Thrombocytopenia.
- Status
- Recruiting
- Phase
- Phase 1/2
- People taking part
- 100 people, planned
- Started
- 7 Feb 2025
- Planned end
- 31 Dec 2025
- Type of study
- Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- Eltrombopag 25 MG
- Prednisolone
- Record updated
- 18 February 2025
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with newly diagnosed primary immune thrombocytopenia (ITP), a condition where the immune system destroys platelets. It compares eltrombopag plus prednisolone with placebo plus prednisolone.
- Age
- 18 to 70 years
- Sex
- All sexes
- Disease stage
- Newly diagnosed ITP. Persistent or chronic ITP cannot join.
- Biomarker or test result
- Platelet count ≤ 30x109/L
Main reasons for not taking part
- Pregnant women
- ITP caused by another disease, such as SLE, anti-phospholipid syndrome, Evans syndrome, HCV or H Pylori
- Recent vaccination, recent viral infection or fever
- Known chronic kidney failure or liver disease
- Grade 3 or 4 bleeding when first seen
The registry criteria, word for word
Show all 10 criteriaShow less
Who can take part
- Patients with newly diagnosed ITP
- Platelet Count ≤ 30x109/L
- Age between 18 to 70 years
Who cannot take part
- Secondary ITP- ITP due to SLE, Anti-phospholipid syndrome, Evans syndrome, HCV or H Pylori associated ITP
- History of vaccination, recent viral infection, fever
- Evan's Syndrome
- Known case of chronic renal failure or liver diseases
- Grade 3 or 4 bleeding at presentation
- Persistent or chronic ITP
- Pregnant women
The main criteria, as questions
These questions come from the eligibility criteria published for this trial. They help you read the criteria and prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.
- Are you between 18 and 70 years old?
This trial is currently available in Bangladesh.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This will be a double-blind, placebo-control, randomized clinical trial conducted in the Department of Hematology, DMCH for one year. This study will help to establish the role of eltrombopag as a first-line therapy in newly diagnosed ITP. Newly diagnosed ITP patients will be selected after meeting inclusion and exclusion criteria, they will be thoroughly informed about the study, used drugs, randomization, risks, benefits, and follow-up. If they agree to participate, their consent will be taken and they will be enrolled in the study. A detailed history and clinical exam will be done. Primary investigation will be - CBC PBF, RBS, ANA, TSH, Anti H. pyloriIgG, Anti-HCV, APTT, and BMS (if indicated). The main outcome variable will be platelet count and number of spontaneous bleeding. Total sample size would be 100 (50 in each group). Enrolled patients would be divided into two groups (1:1) by block randomization. One group will get Eltrombopag\& Prednisolone and other group will get Eltrombopag\& Placebo. Researchers or any one related to the study in DMCH, patients \& their attendants, no one will know which patient will get placebo or eltrombopag. Only a respectable third party will know the information. A patient would be followed up on 1st, 2nd and 4th week of starting therapy. Patients would be evaluated in every follow up by history, physical examination and investigation. History of any spontaneous bleeding event, any discomfort or new symptoms science last follow up will be noted. General examination will be performed in every follow-up. CBC, RBS, ALT, AST, creatinine will be done in every follow-up. Data will be collected on a pre-designed case record form and will be collected through face-to-face interviews, physical examination, and laboratory reports. After data collection data will be edited, cleaned, and prepared for analysis at the end of the study. The statistical analysis will be conducted using SPSS version 25 statistical software. The results of the study will be published in national and international journals.
The 2 groups in the trial
- Eltrombopag ArmTreatment being tested
Eltrombopag + Prednsolone
Treatment: Eltrombopag 25 MG and Prednisolone
- Prednisolone alone armPlacebo, for comparison
Placebo + Prednisolone
Treatment: Prednisolone
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Efficacy of Eltrombopag & Prednisolone Versus Prednisolone Monotherapy in Newly Diagnosed Immune Thrombocytopenia- A Randomized Control Trial
- Plain-language title
- Eltrombopag added to prednisolone for newly diagnosed immune thrombocytopeniaGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 14 November 2026.
- Criteria questions
- Built from NCT06531018, who can take part
- Record updated
- 18 February 2025